Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
15.97
+0.53 (3.43%)
At close: Aug 13, 2025, 4:00 PM
15.50
-0.47 (-2.94%)
Pre-market: Aug 14, 2025, 8:56 AM EDT
Seres Therapeutics Analyst Ratings
Total Analysts
4
Consensus Rating
Hold
Price Target
$73.67
Upside
+361.30%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $1.25 → $6 | Strong Buy → Hold | Downgrades | $1.25 → $6 | -62.43% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +56.54% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $20 → $15 | Strong Sell | Maintains | $20 → $15 | -6.07% | Mar 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +1,152.35% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +56.54% | Nov 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Oct 24, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +1,152.35% | Sep 13, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +1,152.35% | Aug 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +56.54% | Aug 14, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 7, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $200 | Strong Buy | Maintains | $300 → $200 | +1,152.35% | Jun 7, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $100 → $80 | Buy | Maintains | $100 → $80 | +400.94% | May 9, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $160 → $120 | Strong Buy | Maintains | $160 → $120 | +651.41% | May 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $180 → $100 | Buy | Maintains | $180 → $100 | +526.17% | Mar 6, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $200 → $160 | Strong Buy | Maintains | $200 → $160 | +901.88% | Mar 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $200 → $180 | Buy | Maintains | $200 → $180 | +1,027.11% | Jan 16, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.